Regulation of mRNA Expression of MDR1, MRP1, MRP2 and MRP3 by Prototypical Microsomal Enzyme Inducers in Primary Cultures of Human and Rat Hepatocytes

The mRNA induction of various transporters by rifampicin (Rif), dexamethasone (Dex) and omeprazole (Ome) was investigated in primary cultures of cryopreserved human and rat hepatocytes. Analysis was performed by quantitative real­time RT­PCR using primers and TaqMan probes. In primary cultures of hu...

Full description

Saved in:
Bibliographic Details
Published inDRUG METABOLISM AND PHARMACOKINETICS Vol. 21; no. 4; pp. 297 - 307
Main Authors Nishimura, Masuhiro, Koeda, Akiko, Suzuki, Emako, Kawano, Yuichi, Nakayama, Mitsuo, Satoh, Tetsuo, Narimatsu, Shizuo, Naito, Shinsaku
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2006
Japanese Society for the Study of Xenobiotics
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The mRNA induction of various transporters by rifampicin (Rif), dexamethasone (Dex) and omeprazole (Ome) was investigated in primary cultures of cryopreserved human and rat hepatocytes. Analysis was performed by quantitative real­time RT­PCR using primers and TaqMan probes. In primary cultures of human hepatocytes, mRNA levels of MDR and MRP1 were increased by about 1.5 fold and 1.3 fold, respectively, by exposure to Rif at 2 to 50μM as compared with 0.1% DMSO­treated controls. MRP2 mRNA levels in the same human hepatocytes were significantly increased by 1.2 to 1.8 fold by exposure to Rif at 50μM as compared with controls. In primary cultures of rat hepatocytes, Mdr1a and Mdr1b mRNA levels were not increased or only slightly increased at 24hr by exposure to any of the inducers at 2, 10 or 50μM. Mrp2 mRNA levels in the same rat hepatocytes were significantly increased by 7 to 45 fold by exposure to Dex at 2μM as compared with controls. Based on the species differences observed in the present study, primary cultures of cryopreserved hepatocytes from both the human and rat should be useful in preclinical drug development for evaluating candidate drugs for transporter induction.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1347-4367
1880-0920
DOI:10.2133/dmpk.21.297